Cargando…

Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells

Receptor tyrosine kinase-like orphan receptor 2 (ROR2) has been identified as a highly relevant tumor-associated antigen in a variety of cancer indications of high unmet medical need, including renal cell carcinoma and osteosarcoma, making it an attractive target for targeted cancer therapy. Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Hellmann, Ina, Waldmeier, Lorenz, Bannwarth-Escher, Marie-Christine, Maslova, Kseniya, Wolter, Fabian I., Grawunder, Ulf, Beerli, Roger R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224377/
https://www.ncbi.nlm.nih.gov/pubmed/30450096
http://dx.doi.org/10.3389/fimmu.2018.02490
_version_ 1783369585294049280
author Hellmann, Ina
Waldmeier, Lorenz
Bannwarth-Escher, Marie-Christine
Maslova, Kseniya
Wolter, Fabian I.
Grawunder, Ulf
Beerli, Roger R.
author_facet Hellmann, Ina
Waldmeier, Lorenz
Bannwarth-Escher, Marie-Christine
Maslova, Kseniya
Wolter, Fabian I.
Grawunder, Ulf
Beerli, Roger R.
author_sort Hellmann, Ina
collection PubMed
description Receptor tyrosine kinase-like orphan receptor 2 (ROR2) has been identified as a highly relevant tumor-associated antigen in a variety of cancer indications of high unmet medical need, including renal cell carcinoma and osteosarcoma, making it an attractive target for targeted cancer therapy. Here, we describe the de novo discovery of fully human ROR2-specific antibodies and potent antibody drug conjugates (ADCs) derived thereof by combining antibody discovery from immune libraries of human immunoglobulin transgenic animals using the Transpo-mAb mammalian cell-based IgG display platform with functional screening for internalizing antibodies using a secondary ADC assay. The discovery strategy entailed immunization of transgenic mice with the cancer antigen ROR2, harboring transgenic IgH and IgL chain gene loci with limited number of fully human V, D, and J gene segments. This was followed by recovering antibody repertoires from the immunized animals, expressing and screening them as full-length human IgG libraries by transposon-mediated display in progenitor B lymphocytes (“Transpo-mAb Display”) for ROR2 binding. Individual cellular “Transpo-mAb” clones isolated by single cell sorting and capable of expressing membrane-bound as well as secreted human IgG were directly screened during antibody discovery, not only for high affinity binding to human ROR2, but also functionally as ADCs using a cytotoxicity assay with a secondary anti-human IgG-toxin-conjugate. Using this strategy, we identified and validated 12 fully human, monoclonal anti-human ROR2 antibodies with nanomolar affinities that are highly potent as ADCs and could be promising candidates for the therapy of human cancer. The screening for functional and internalizing antibodies during the early phase of antibody discovery demonstrates the utility of the mammalian cell-based Transpo-mAb Display platform to select for functional binders and as a powerful tool to improve the efficiency for the development of therapeutically relevant ADCs.
format Online
Article
Text
id pubmed-6224377
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62243772018-11-16 Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells Hellmann, Ina Waldmeier, Lorenz Bannwarth-Escher, Marie-Christine Maslova, Kseniya Wolter, Fabian I. Grawunder, Ulf Beerli, Roger R. Front Immunol Immunology Receptor tyrosine kinase-like orphan receptor 2 (ROR2) has been identified as a highly relevant tumor-associated antigen in a variety of cancer indications of high unmet medical need, including renal cell carcinoma and osteosarcoma, making it an attractive target for targeted cancer therapy. Here, we describe the de novo discovery of fully human ROR2-specific antibodies and potent antibody drug conjugates (ADCs) derived thereof by combining antibody discovery from immune libraries of human immunoglobulin transgenic animals using the Transpo-mAb mammalian cell-based IgG display platform with functional screening for internalizing antibodies using a secondary ADC assay. The discovery strategy entailed immunization of transgenic mice with the cancer antigen ROR2, harboring transgenic IgH and IgL chain gene loci with limited number of fully human V, D, and J gene segments. This was followed by recovering antibody repertoires from the immunized animals, expressing and screening them as full-length human IgG libraries by transposon-mediated display in progenitor B lymphocytes (“Transpo-mAb Display”) for ROR2 binding. Individual cellular “Transpo-mAb” clones isolated by single cell sorting and capable of expressing membrane-bound as well as secreted human IgG were directly screened during antibody discovery, not only for high affinity binding to human ROR2, but also functionally as ADCs using a cytotoxicity assay with a secondary anti-human IgG-toxin-conjugate. Using this strategy, we identified and validated 12 fully human, monoclonal anti-human ROR2 antibodies with nanomolar affinities that are highly potent as ADCs and could be promising candidates for the therapy of human cancer. The screening for functional and internalizing antibodies during the early phase of antibody discovery demonstrates the utility of the mammalian cell-based Transpo-mAb Display platform to select for functional binders and as a powerful tool to improve the efficiency for the development of therapeutically relevant ADCs. Frontiers Media S.A. 2018-11-02 /pmc/articles/PMC6224377/ /pubmed/30450096 http://dx.doi.org/10.3389/fimmu.2018.02490 Text en Copyright © 2018 Hellmann, Waldmeier, Bannwarth-Escher, Maslova, Wolter, Grawunder and Beerli. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Hellmann, Ina
Waldmeier, Lorenz
Bannwarth-Escher, Marie-Christine
Maslova, Kseniya
Wolter, Fabian I.
Grawunder, Ulf
Beerli, Roger R.
Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells
title Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells
title_full Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells
title_fullStr Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells
title_full_unstemmed Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells
title_short Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells
title_sort novel antibody drug conjugates targeting tumor-associated receptor tyrosine kinase ror2 by functional screening of fully human antibody libraries using transpo-mab display on progenitor b cells
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224377/
https://www.ncbi.nlm.nih.gov/pubmed/30450096
http://dx.doi.org/10.3389/fimmu.2018.02490
work_keys_str_mv AT hellmannina novelantibodydrugconjugatestargetingtumorassociatedreceptortyrosinekinaseror2byfunctionalscreeningoffullyhumanantibodylibrariesusingtranspomabdisplayonprogenitorbcells
AT waldmeierlorenz novelantibodydrugconjugatestargetingtumorassociatedreceptortyrosinekinaseror2byfunctionalscreeningoffullyhumanantibodylibrariesusingtranspomabdisplayonprogenitorbcells
AT bannwartheschermariechristine novelantibodydrugconjugatestargetingtumorassociatedreceptortyrosinekinaseror2byfunctionalscreeningoffullyhumanantibodylibrariesusingtranspomabdisplayonprogenitorbcells
AT maslovakseniya novelantibodydrugconjugatestargetingtumorassociatedreceptortyrosinekinaseror2byfunctionalscreeningoffullyhumanantibodylibrariesusingtranspomabdisplayonprogenitorbcells
AT wolterfabiani novelantibodydrugconjugatestargetingtumorassociatedreceptortyrosinekinaseror2byfunctionalscreeningoffullyhumanantibodylibrariesusingtranspomabdisplayonprogenitorbcells
AT grawunderulf novelantibodydrugconjugatestargetingtumorassociatedreceptortyrosinekinaseror2byfunctionalscreeningoffullyhumanantibodylibrariesusingtranspomabdisplayonprogenitorbcells
AT beerlirogerr novelantibodydrugconjugatestargetingtumorassociatedreceptortyrosinekinaseror2byfunctionalscreeningoffullyhumanantibodylibrariesusingtranspomabdisplayonprogenitorbcells